Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Michigan: - Hickman Cancer Center — Adrian, Michigan
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health Medical Center - Brighton — Brighton, Michigan
Phase 3 Recruiting Academic/Other
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal a…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health Medical Center - Brighton — Brighton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
Phase 3 Recruiting Academic/Other
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- McLaren Cancer Institute-Bay City — Bay City, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health Medical Center - Brighton — Brighton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
- Children's Hospital of Michigan — Detroit, Michigan
- Henry Ford Health Saint John Hospital — Detroit, Michigan
- Michigan State University — East Lansing, Michigan
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan
Phase 3 Recruiting Industry
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …
Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in Michigan: - Research Site — Ann Arbor, Michigan
- Research Site — Detroit, Michigan
- Research Site — Ypsilanti, Michigan
Phase 3 Recruiting Industry
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the se…
Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT07188558
Sites in Michigan: - Corewell Health — Grand Rapids, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06717347
Sites in Michigan: - Karmanos Cancer Institute ( Site 0174) — Detroit, Michigan
- Corewell Health ( Site 0130) — Grand Rapids, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had be…
Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Michigan: - University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Battle Creek Health Systm — Battle Creek, Michigan
- Karmanos Cancer Institute - Wayne State University — Detroit, Michigan
Phase 3 Recruiting Industry
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell ly…
Sponsor: Corvus Pharmaceuticals, Inc.
NCT ID: NCT06561048
Sites in Michigan: - Roger Cancer Center University of Michigan Health — Ann Arbor, Michigan
Phase 3 Recruiting Industry
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treat…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06091865
Sites in Michigan: - Henry Ford Health System — Detroit, Michigan
- Cancer and Hematology Centers of Western Michigan — Grand Rapids, Michigan
Phase 3 Recruiting Industry
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+),…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06784752
Sites in Michigan: - Henry Ford Hospital — Detroit, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in Michigan: - University of Michigan Health System — Ann Arbor, Michigan
Phase 3 Recruiting Industry
Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Saf…
Sponsor: Acrotech Biopharma Inc.
NCT ID: NCT06072131
Sites in Michigan: - Henry Ford Health System — Detroit, Michigan
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- Corewell Health Dearborn Hospital — Dearborn, Michigan
- Children's Hospital of Michigan — Detroit, Michigan
- Michigan State University — East Lansing, Michigan
Phase 1, Phase 2 Recruiting Network
This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04315324
Sites in Michigan: - Bronson Battle Creek — Battle Creek, Michigan
- Wayne State University/Karmanos Cancer Institute — Detroit, Michigan
- Weisberg Cancer Treatment Center — Farmington Hills, Michigan
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan
Phase 2 Recruiting NIH
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutin…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04840602
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health Medical Center - Brighton — Brighton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
- Trinity Health Medical Center - Canton — Canton, Michigan
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan
- Bronson Methodist Hospital — Kalamazoo, Michigan
Phase 2 Recruiting Network
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health Medical Center - Brighton — Brighton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
- Trinity Health Medical Center - Canton — Canton, Michigan
Phase 2 Recruiting Academic/Other
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hemato…
Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
NCT ID: NCT03509961
Sites in Michigan: - Helen DeVos Children's Hospital at Spectrum Health — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- posi…
Sponsor: Nuvalent Inc.
NCT ID: NCT05384626
Sites in Michigan: - Henry Ford Cancer Institute — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Michigan: - University of Michigan Hospital — Ann Arbor, Michigan
- South Texas Accelerated Research Therapeutics (Start) - Midwest Location — Grand Rapids, Michigan
Phase 2 Recruiting Network
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who …
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT06859424
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 2 Recruiting Academic/Other
Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Days 1 and 8, cisplatin 75 mg/m2 IV on Da…
Sponsor: Dipenkumar Modi
NCT ID: NCT05852717
Sites in Michigan: - Karmanos Cancer Center (Wayne State University) — Detroit, Michigan